Laxmi, Tilganga sign deal

Kathmandu, November 8: Laxmi Bank has signed a Memorandum of Understanding (MoU)with Nepal Eye program- Tilganga Institute of and Ophthalmology to support diagnosis treatment of Childhood Eye Cancer technically known as Retinoblastoma. Ajaya Bikram Shah, CEO of the bank and Reeta Gurung, CEO of Tilganga Institute of Ophthalmology inked the deal on behalf of their respective organizations.

As per the MoU, the bank shall provide funds amounting to NPR 500,000.00 as an initiative under Corporate Social Responsibility (CSR) for the diagnosis and treatment of Retinoblastoma patients from deprived financial background.

Retinoblastoma is a rare eye cancer of childhood that arises in the retina. It is the most common intraocular malignancy of infancy and childhood; with an incidence of 1 in 15,000 to 1 in 18,000 live births worldwide, mostly occurring to children age from birth till 5 years. If the disease is diagnosed and treated on time, chances of salvage of life, eye, and vision is very high. In Nepal, the Tilganga Institute of Ophthalmology has started its treatment, which includes Chemotherapy, Laser therapy, Plaque Brachytherapy and surgery where needed.

Our approach is to support Sustainable Development Goals of Good Health and Well-being by providing financial support to the hospital for diagnosis and treatment of Childhood Eye Cancer, claims the bank.